A Phase 4 interventional study of Esketamine and SSRI/SNRI in Depressive Disorder, Major, sponsored by Janssen-Cilag Ltd.. Completed at 59 sites in 14 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2025-09-18.
Sponsored by Janssen-Cilag Ltd. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing esketamine in Depressive Disorder, Major — 5 open to participants now, 5 under way, 2 of them phase 3. Esketamine · Depressive Disorder, Major.
Among the 17 studies testing esketamine in Depressive Disorder, Major, this one is the 6th largest by enrollment, is one of 2 that started in 2021, is one of 4 in phase 4, and was the 10th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →5 of the 17 studies testing esketamine in Depressive Disorder, Major are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Brazil, Hungary and 4 more countries
Ages 12–17
Dr. Inge Winter · Sites in Austria, Germany, Greece and 3 more countries
Ages 18–65
Royal North Shore Hospital · Sites in Australia
Ages 18–65
Massachusetts General Hospital · Sites in United States
Ages 18–70
Medical University of Vienna · Sites in Austria
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 183 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 147 across the 17 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen-Cilag Ltd., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen-Cilag Ltd. is the lead sponsor of 35 studies on the registry; 4 are open to participants now.
59 studies in Depressive Disorder, Major by Johnson & Johnson: 5 open now, 5 under way, 5 of them phase 3. Of 53 finished, 26 (49%) have results posted.
Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, this one is the 28th largest by enrollment of the 52 interventional ones that give a count, is one of 6 that started in 2021, is one of 4 in phase 4, and was the 41st registered.
Johnson & Johnson’s Depressive Disorder, Major studies by the year they started, since 2002.
1 of the studies testing esketamine in Depressive Disorder, Major that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05450432Massachusetts General HospitalLong-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing esketamine in Depressive Disorder, Major, from their registry updates:
Among Johnson & Johnson’s 59 in Depressive Disorder, Major:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to assess the long-term safety and tolerability of esketamine nasal spray in combination with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) in participants who have completed 32 weeks of esketamine nasal spray treatment in Study 54135419TRD3013 (NCT04338321).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who were randomly assigned to the esketamine arm in Study 54135419TRD3013 (NCT04338321), had esketamine nasal spray administered through Week 30 (every 2 weeks dosing) or Week 31 (once weekly dosing), completed the maintenance phase at Week 32 will continue to receive esketamine nasal spray once weekly or every 2 weeks along with serotonin-norepinephrine reuptake inhibitor/selective serotonin reuptake inhibitor (SSRI/SNRI) in this long-term extension (LTE) study. The duration of the study participation is 2 years or when esketamine is commercially available.
Drug: Esketamine · Drug: SSRI/SNRI
Esketamine will be self-administered as nasal spray.
Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the summary of product characteristics (SmPC) (or local equivalent, if applicable). During this LTE study, investigators will be allowed to switch individual participant's SSRI/SNRI for tolerability issues.
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
Percentage of participants with TEAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious adverse events.
Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
Incidence Rate of Treatment-emergent Adverse Events (TEAEs)
Incidence rate of TEAEs were reported. AE Incidence rate was defined as incidence rate per 100 patient-months = (number of participants with AE divided by sum of days at risk for AE) \* 100\*365.25/12. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious adverse events.
Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
Percentage of participants with TESAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent.
Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
Incidence Rate of Treatment-emergent Serious Adverse Events (TESAEs)
Incidence rate of with TESAEs were reported. AE Incidence rate was defined as incidence rate per 100 patient-months = (number of participants with AE divided by sum of days at risk for AE) \* 100\*365.25/12. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent.
Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
Percentage of of Participants With TEAEs Leading to Death
Percentage of participants with TEAEs leading to death were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious adverse events.
Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
Incidence Rate of TEAEs Leading to Death
Incidence rate of TEAEs leading to death were reported. AE Incidence rate was defined as incidence rate per 100 patient-months = (number of participants with AE divided by sum of days at risk for AE) \* 100\*365.25/12. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious adverse events.
Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
Percentage of Participants With Treatment-emergent AEs of Special Interest (AESIs)
Percentage of participants with TEAEs of special interest were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious AEs. AEs of special interest were separately grouped by categories sedation, dissociation, suicidality, suggestive of abuse potential, cystitis and hepatic impairment.
Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
Incidence Rate of Treatment-emergent AEs of Special Interest (AESIs)
AE Incidence rate: incidence rate per 100 patient-months=(number of participants with AE divided by sum of days at risk for AE)\* 100\*365.25/12. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with intervention. SAE: AE resulting in any following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial intervention administration up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious AEs. AEs of special interest were grouped as categories sedation, dissociation, suicidality, suggestive of abuse potential, cystitis and hepatic impairment.
Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
Number of Participants With Suicidal Ideation and Behavior in Study 54135419TRD4010 as Assessed by Columbia-suicide Severity Rating Scale (C-SSRS) Score
Number of participants with suicidal ideation and behavior in study 54135419TRD4010 as assessed by C-SSRS score were reported. C-SSRS score: an assessment tool that evaluated suicidal ideation and behavior. Suicidal ideation (5 items): wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, and active suicidal ideation with specific plan and intent. Suicidal behavior (5 items): preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt (non-fatal), and suicide. Total score from 10 categories was summarized into 3 categories: No suicidal ideation or behavior (0), Suicidal ideation (1 to 5), Suicidal behavior (6 to 10). Total score ranged from 0 to 10. Higher scores indicated more severe suicidal ideation and behavior.
Time frame: Baseline (Day 1 of Study 54135419TRD3013) up to Week 104 of study 54135419TRD4010 (up to Week 136)
Percentage of Participants With No Relapse and Without Discontinuation Until the End of the Prospective Observation Period at Week 104
Relapse was defined by any of the following: a) Worsening of depressive symptoms as indicated by Montgomery-Asberg Depression Rating Scale (MADRS) total score \>=22 confirmed by 1 additional assessment of MADRS total score \>=22 within the next 5 to 31 days. b) Any psychiatric hospitalization for: 1) worsening of depression, 2) suicide prevention or due to a suicide attempt for any of these events. c) Suicide attempt, completed suicide, or any other clinically relevant event determined per investigator's clinical judgment to be indicative of relapse of depressive illness, but for which participant was not hospitalized. MADRS scale consisted of 10 items, scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 0 to 60. Higher scores represented a more severe condition.
Time frame: Baseline (Day 1 of Study 54135419TRD3013) up to Week 104 of study 54135419TRD4010 (up to Week 136)
Change From Baseline of Study 54135419TRD3013 in Clinician-rated Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Change from baseline of study 54135419TRD3013 in Clinician-rated MADRS total score were reported. MADRS was a clinician-rated scale designed to measure depression severity and to detect changes due to antidepressant treatment. The scale consists of 10 items , scored from 0 (item is not present or normal) to 6 (severe or continuous presence of symptoms), summed up for a total possible score range of 0 to 60. Higher scores represented a more severe condition. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts.
Time frame: Baseline (Day 1 of study 54135419TRD3013) up to weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, and 104 of study 54135419TRD4010
Change From Baseline of Study 54135419TRD3013 in Clinician-rated Montgomery-Asberg Depression Rating Scale (MADRS) Score Individual Items
Change from Baseline of Study 54135419TRD3013 in Clinician-rated MADRS Score Individual Items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts) were reported. MADRS was a clinician-rated scale designed to measure depression severity and to detect changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), summed up for a total possible score range of 0 to 60. Higher scores represent a more severe condition.
Time frame: Baseline (Day 1 of study 54135419TRD3013) up to weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, and 104 of study 54135419TRD4010
Change From Baseline of Study 54135419TRD3013 in Clinical Global Impression -Severity (CGI-S) Scale Score
Change from Baseline of Study 54135419TRD3013 in CGI-S scale score were reported. The CGI-S provided an overall clinician-determined summary measure of the severity of the participant's illness that took into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluated the severity of psychopathology on a scale of 1 to 7: where, 1 = normal (not ill); 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participant's. Negative change in score indicated improvement. Participant's with a score of zero were considered missing.
Time frame: Baseline (Day 1 of study 54135419TRD3013) up to weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, and 104 of study 54135419TRD4010
Change From Baseline of Study 54135419TRD3013 in Patient Health Questionnaire (PHQ) 9-item Total Score
Change from Baseline of Study 54135419TRD3013 in PHQ 9-item total score were reported. The PHQ-9 was a validated 9-item, patient-reported outcome (PRO) measure to assess depressive symptoms. Each item was rated on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses were summed to a total score with a range of 0 to 27. Higher scores indicated greater severity of depressive symptoms.
Time frame: Baseline (Day 1 of study 54135419TRD3013) up to weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, and 104 of study 54135419TRD4010
Change From Baseline of Study 54135419TRD3013 in European Quality of Life (EuroQol) 5 Dimension 5-Level (EQ-5D-5L): Health Status Index
Change from baseline of Study 54135419TRD3013 in EQ-5D-5LQuestionnaire Score: health status index were reported. The EQ-5D-5L descriptive system comprised the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions were divided into 5 levels of perceived problems (level 1 = no problem, level 2 = slight problems, level 3 = moderate problems, level 4 = severe problems, level 5 = extreme problems). The participant selected an answer for each of the 5 dimensions considering a response that best matched participant's health "today." Responses were used to generate health status index ranged from -0.594 to 1 (where 1 represents full health and negative values represent health states considered worse than dead). Positive change in score indicated improvement.
Time frame: Baseline (Day 1 of Study 54135419TRD3013) up to weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, and 104 of study 54135419TRD4010
Change From Baseline of Study 54135419TRD3013 in European Quality of Life (EuroQol) 5 Dimension 5-Level (EQ-5D-5L): Visual Analogue Scale (VAS)
Change from baseline of Study 54135419TRD3013 in EQ-5D-5L: visual analogue scale were reported. EQ-VAS self-rating recorded the participant's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Positive change in score indicated improvement.
Time frame: Baseline (Day 1 of Study 54135419TRD3013) up to weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, and 104 of study 54135419TRD4010
| Milestone | Esketamine Nasal Spray + Oral Antidepressant (AD) |
|---|---|
| Started | 183 |
| Treated with esketamine 28 mg | 2 |
| Treated with esketamine 56 mg | 68 |
| Treated with esketamine 84 mg | 113 |
| Treated with oral ad | 182 |
| Completed | 148 |
| Not completed | 35 |
| Withdrew: Adverse event | 6 |
| Withdrew: Death | 1 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Physician decision | 1 |
| Withdrew: Withdrawal by subject | 19 |
| Withdrew: Site terminated by sponsor | 1 |
| Withdrew: Sponsor decision | 5 |
| Withdrew: Other | 1 |
Percentage of participants with TEAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious adverse events.
| percentage of participants | Esketamine Nasal Spray + Oral Antidepressant (AD) |
|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | 88.0 |
Incidence rate of TEAEs were reported. AE Incidence rate was defined as incidence rate per 100 patient-months = (number of participants with AE divided by sum of days at risk for AE) \* 100\*365.25/12. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious adverse events.
| AEs per 100 patient-months | Esketamine Nasal Spray + Oral Antidepressant (AD) |
|---|---|
| Incidence Rate of Treatment-emergent Adverse Events (TEAEs) | 17.33 (14.85 to 20.23) |
Percentage of participants with TESAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent.
| percentage of participants | Esketamine Nasal Spray + Oral Antidepressant (AD) |
|---|---|
| Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs) | 6.0 |
Incidence rate of with TESAEs were reported. AE Incidence rate was defined as incidence rate per 100 patient-months = (number of participants with AE divided by sum of days at risk for AE) \* 100\*365.25/12. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent.
| AEs per 100 patient-months | Esketamine Nasal Spray + Oral Antidepressant (AD) |
|---|---|
| Incidence Rate of Treatment-emergent Serious Adverse Events (TESAEs) | 0.28 (0.16 to 0.51) |
Percentage of participants with TEAEs leading to death were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious adverse events.
| percentage of participants | Esketamine Nasal Spray + Oral Antidepressant (AD) |
|---|---|
| Percentage of of Participants With TEAEs Leading to Death | 0.6 (0.16 to 0.51) |
Incidence rate of TEAEs leading to death were reported. AE Incidence rate was defined as incidence rate per 100 patient-months = (number of participants with AE divided by sum of days at risk for AE) \* 100\*365.25/12. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious adverse events.
| AEs per 100 patient-months | Esketamine Nasal Spray + Oral Antidepressant (AD) |
|---|---|
| Incidence Rate of TEAEs Leading to Death | 0.03 (0.00 to 0.18) |
Percentage of participants with TEAEs of special interest were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with intervention. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial administration of study intervention up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious AEs. AEs of special interest were separately grouped by categories sedation, dissociation, suicidality, suggestive of abuse potential, cystitis and hepatic impairment.
| percentage of participants | Esketamine Nasal Spray + Oral Antidepressant (AD) |
|---|---|
| Sedation | 16.9 |
| Dissociation | 12.0 |
| Suicidality | 3.8 |
| Suggestive of abuse potential | 37.7 |
| Cystitis | 0.5 |
AE Incidence rate: incidence rate per 100 patient-months=(number of participants with AE divided by sum of days at risk for AE)\* 100\*365.25/12. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with intervention. SAE: AE resulting in any following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurring at or after the initial intervention administration up to 30 days after last dose in Study 54135419TRD4010 was considered to be treatment emergent. TEAEs included both serious and non-serious AEs. AEs of special interest were grouped as categories sedation, dissociation, suicidality, suggestive of abuse potential, cystitis and hepatic impairment.
| AEs per 100 patient-months | Esketamine Nasal Spray + Oral Antidepressant (AD) |
|---|---|
| Sedation | 0.91 |
| Dissociation | 0.61 |
| Suicidality | 0.18 |
| Suggestive of abuse potential | 2.63 |
| Cystitis | 0.03 |
Number of participants with suicidal ideation and behavior in study 54135419TRD4010 as assessed by C-SSRS score were reported. C-SSRS score: an assessment tool that evaluated suicidal ideation and behavior. Suicidal ideation (5 items): wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, and active suicidal ideation with specific plan and intent. Suicidal behavior (5 items): preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt (non-fatal), and suicide. Total score from 10 categories was summarized into 3 categories: No suicidal ideation or behavior (0), Suicidal ideation (1 to 5), Suicidal behavior (6 to 10). Total score ranged from 0 to 10. Higher scores indicated more severe suicidal ideation and behavior.
| Participants | Esketamine Nasal Spray + Oral Antidepressant (AD) |
|---|---|
| No suicidal ideation or behavior | 158 |
| Suicidal ideation | 24 |
| Suicidal behavior | 1 |
Relapse was defined by any of the following: a) Worsening of depressive symptoms as indicated by Montgomery-Asberg Depression Rating Scale (MADRS) total score \>=22 confirmed by 1 additional assessment of MADRS total score \>=22 within the next 5 to 31 days. b) Any psychiatric hospitalization for: 1) worsening of depression, 2) suicide prevention or due to a suicide attempt for any of these events. c) Suicide attempt, completed suicide, or any other clinically relevant event determined per investigator's clinical judgment to be indicative of relapse of depressive illness, but for which participant was not hospitalized. MADRS scale consisted of 10 items, scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 0 to 60. Higher scores represented a more severe condition.
| percentage of participants | Esketamine Nasal Spray + Oral Antidepressant (AD) |
|---|---|
| Percentage of Participants With No Relapse and Without Discontinuation Until the End of the Prospective Observation Period at Week 104 | 79.2 |
Change from baseline of study 54135419TRD3013 in Clinician-rated MADRS total score were reported. MADRS was a clinician-rated scale designed to measure depression severity and to detect changes due to antidepressant treatment. The scale consists of 10 items , scored from 0 (item is not present or normal) to 6 (severe or continuous presence of symptoms), summed up for a total possible score range of 0 to 60. Higher scores represented a more severe condition. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts.
| score on a scale | Esketamine Nasal Spray + Oral Antidepressant (AD) |
|---|---|
| Week 4 | -21.9 ± 8.10 |
| Week 8 | -21.8 ± 7.93 |
| Week 12 | -22.5 ± 7.25 |
| Week 16 | -22.8 ± 7.24 |
| Week 20 | -22.3 ± 7.26 |
| Week 24 | -22.6 ± 6.82 |
| Week 28 | -22.4 ± 7.13 |
| Week 32 | -22.5 ± 7.16 |
| Week 36 | -22.5 ± 8.12 |
| Week 40 | -22.7 ± 7.03 |
| Week 44 | -22.9 ± 7.41 |
| Week 48 | -22.9 ± 7.19 |
| Week 52 | -22.6 ± 7.13 |
| Week 56 | -23.0 ± 6.88 |
| Week 60 | -23.1 ± 7.11 |
| Week 64 | -23.4 ± 7.52 |
| Week 68 | -23.2 ± 7.10 |
| Week 72 | -23.6 ± 6.98 |
| Week 76 | -23.8 ± 6.91 |
| Week 80 | -23.7 ± 7.19 |
| Week 84 | -23.6 ± 6.87 |
| Week 88 | -24.4 ± 6.78 |
| Week 92 | -24.3 ± 7.17 |
| Week 96 | -24.7 ± 6.57 |
| Week 100 | -24.9 ± 6.39 |
| Week 104 | -25.3 ± 6.69 |
Change from Baseline of Study 54135419TRD3013 in Clinician-rated MADRS Score Individual Items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts) were reported. MADRS was a clinician-rated scale designed to measure depression severity and to detect changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), summed up for a total possible score range of 0 to 60. Higher scores represent a more severe condition.
| score on a scale | Esketamine Nasal Spray + Oral Antidepressant (AD) |
|---|---|
| Week 4: Apparent Sadness | -3.0 ± 1.38 |
| Week 8: Apparent Sadness | -3.0 ± 1.45 |
| Week 12: Apparent Sadness | -3.0 ± 1.34 |
| Week 16: Apparent Sadness | -3.1 ± 1.34 |
| Week 20: Apparent Sadness | -3.1 ± 1.31 |
| Week 24: Apparent Sadness | -2.9 ± 1.36 |
| Week 28: Apparent Sadness | -3.0 ± 1.33 |
| Week 32: Apparent Sadness | -3.0 ± 1.28 |
| Week 36: Apparent Sadness | -3.0 ± 1.42 |
| Week 40: Apparent Sadness | -3.0 ± 1.36 |
| Week 44: Apparent Sadness | -3.1 ± 1.38 |
| Week 48: Apparent Sadness | -3.1 ± 1.34 |
| Week 52: Apparent Sadness | -3.1 ± 1.32 |
| Week 56: Apparent Sadness | -3.1 ± 1.23 |
| Week 60: Apparent Sadness | -3.1 ± 1.24 |
| Week 64: Apparent Sadness | -3.2 ± 1.33 |
| Week 68: Apparent Sadness | -3.1 ± 1.23 |
| Week 72: Apparent Sadness | -3.2 ± 1.21 |
| Week 76: Apparent Sadness | -3.3 ± 1.22 |
| Week 80: Apparent Sadness | -3.3 ± 1.24 |
| Week 84: Apparent Sadness | -3.2 ± 1.15 |
| Week 88: Apparent Sadness | -3.4 ± 1.17 |
| Week 92: Apparent Sadness | -3.3 ± 1.20 |
| Week 96: Apparent Sadness | -3.3 ± 1.20 |
| Week 100: Apparent Sadness | -3.4 ± 1.13 |
| Week 104: Apparent Sadness | -3.5 ± 1.20 |
| Week 4: Reported Sadness | -3.1 ± 1.29 |
| Week 8: Reported Sadness | -3.0 ± 1.38 |
| Week 12: Reported Sadness | -3.0 ± 1.20 |
| Week 16: Reported Sadness | -3.1 ± 1.28 |
| Week 20: Reported Sadness | -3.1 ± 1.24 |
| Week 24: Reported Sadness | -3.1 ± 1.19 |
| Week 28: Reported Sadness | -3.0 ± 1.21 |
| Week 32: Reported Sadness | -3.1 ± 1.18 |
| Week 36: Reported Sadness | -3.0 ± 1.23 |
| Week 40: Reported Sadness | -3.2 ± 1.18 |
| Week 44: Reported Sadness | -3.1 ± 1.23 |
| Week 48: Reported Sadness | -3.1 ± 1.22 |
| Week 52: Reported Sadness | -3.1 ± 1.19 |
| Week 56: Reported Sadness | -3.2 ± 1.12 |
| Week 60: Reported Sadness | -3.3 ± 1.14 |
| Week 64: Reported Sadness | -3.3 ± 1.26 |
| Week 68: Reported Sadness | -3.2 ± 1.24 |
| Week 72: Reported Sadness | -3.2 ± 1.20 |
| Week 76: Reported Sadness | -3.3 ± 1.16 |
| Week 80: Reported Sadness | -3.3 ± 1.12 |
| Week 84: Reported Sadness | -3.3 ± 1.10 |
| Week 88: Reported Sadness | -3.3 ± 1.14 |
| Week 92: Reported Sadness | -3.3 ± 1.24 |
| Week 96: Reported Sadness | -3.4 ± 1.03 |
| Week 100: Reported Sadness | -3.4 ± 1.05 |
| Week 104: Reported Sadness | -3.5 ± 1.07 |
| Week 4: Inner Tension | -1.8 ± 1.19 |
| Week 8: Inner Tension | -1.8 ± 1.18 |
| Week 12: Inner Tension | -1.9 ± 1.20 |
| Week 16: Inner Tension | -1.9 ± 1.15 |
| Week 20: Inner Tension | -1.8 ± 1.19 |
| Week 24: Inner Tension | -1.9 ± 1.21 |
| Week 28: Inner Tension | -1.8 ± 1.23 |
| Week 32: Inner Tension | -1.9 ± 1.23 |
| Week 36: Inner Tension | -2.0 ± 1.07 |
| Week 40: Inner Tension | -1.8 ± 1.17 |
| Week 44: Inner Tension | -1.9 ± 1.20 |
| Week 48: Inner Tension | -2.0 ± 1.25 |
| Week 52: Inner Tension | -1.9 ± 1.16 |
| Week 56: Inner Tension | -2.0 ± 1.20 |
| Week 60: Inner Tension | -1.9 ± 1.32 |
| Week 64: Inner Tension | -2.0 ± 1.34 |
| Week 68: Inner Tension | -1.9 ± 1.26 |
| Week 72: Inner Tension | -2.0 ± 1.26 |
| Week 76: Inner Tension | -2.0 ± 1.22 |
| Week 80: Inner Tension | -2.1 ± 1.13 |
| Week 84: Inner Tension | -2.0 ± 1.28 |
| Week 88: Inner Tension | -2.0 ± 1.20 |
| Week 92: Inner Tension | -2.0 ± 1.16 |
| Week 96: Inner Tension | -2.0 ± 1.14 |
| Week 100: Inner Tension | -2.0 ± 1.18 |
| Week 104: Inner Tension | -2.1 ± 1.22 |
| Week 4: Reduced Sleep | -2.1 ± 1.72 |
| Week 8: Reduced Sleep | -2.2 ± 1.64 |
| Week 12: Reduced Sleep | -2.2 ± 1.63 |
| Week 16: Reduced Sleep | -2.2 ± 1.75 |
| Week 20: Reduced Sleep | -2.3 ± 1.72 |
| Week 24: Reduced Sleep | -2.2 ± 1.68 |
| Week 28: Reduced Sleep | -2.2 ± 1.72 |
| Week 32: Reduced Sleep | -2.3 ± 1.70 |
| Week 36: Reduced Sleep | -2.3 ± 1.81 |
| Week 40: Reduced Sleep | -2.3 ± 1.76 |
| Week 44: Reduced Sleep | -2.4 ± 1.61 |
| Week 48: Reduced Sleep | -2.3 ± 1.69 |
| Week 52: Reduced Sleep | -2.2 ± 1.64 |
| Week 56: Reduced Sleep | -2.2 ± 1.73 |
| Week 60: Reduced Sleep | -2.3 ± 1.62 |
| Week 64: Reduced Sleep | -2.2 ± 1.70 |
| Week 68: Reduced Sleep | -2.4 ± 1.82 |
| Week 72: Reduced Sleep | -2.3 ± 1.66 |
| Week 76: Reduced Sleep | -2.4 ± 1.67 |
| Week 80: Reduced Sleep | -2.3 ± 1.84 |
| Week 84: Reduced Sleep | -2.4 ± 1.73 |
| Week 88: Reduced Sleep | -2.5 ± 1.58 |
| Week 92: Reduced Sleep | -2.4 ± 1.70 |
| Week 96: Reduced Sleep | -2.5 ± 1.66 |
| Week 100: Reduced Sleep | -2.5 ± 1.66 |
| Week 104: Reduced Sleep | -2.6 ± 1.76 |
| Week 4: Reduced Appetite | -1.7 ± 1.78 |
| Week 8: Reduced Appetite | -1.7 ± 1.75 |
| Week 12: Reduced Appetite | -1.9 ± 1.68 |
| Week 16: Reduced Appetite | -2.0 ± 1.69 |
| Week 20: Reduced Appetite | -1.8 ± 1.74 |
| Week 24: Reduced Appetite | -1.9 ± 1.74 |
| Week 28: Reduced Appetite | -1.9 ± 1.74 |
| Week 32: Reduced Appetite | -1.9 ± 1.72 |
| Week 36: Reduced Appetite | -1.9 ± 1.81 |
| Week 40: Reduced Appetite | -1.9 ± 1.69 |
| Week 44: Reduced Appetite | -1.9 ± 1.81 |
| Week 48: Reduced Appetite | -1.9 ± 1.73 |
| Week 52: Reduced Appetite | -1.9 ± 1.78 |
| Week 56: Reduced Appetite | -1.9 ± 1.65 |
| Week 60: Reduced Appetite | -1.9 ± 1.68 |
| Week 64: Reduced Appetite | -2.0 ± 1.67 |
| Week 68: Reduced Appetite | -2.0 ± 1.69 |
| Week 72: Reduced Appetite | -2.0 ± 1.64 |
| Week 76: Reduced Appetite | -2.0 ± 1.62 |
| Week 80: Reduced Appetite | -1.9 ± 1.78 |
| Week 84: Reduced Appetite | -2.0 ± 1.70 |
| Week 88: Reduced Appetite | -2.0 ± 1.73 |
| Week 92: Reduced Appetite | -2.0 ± 1.67 |
| Week 96: Reduced Appetite | -2.1 ± 1.61 |
| Week 100: Reduced Appetite | -2.0 ± 1.69 |
| Week 104: Reduced Appetite | -2.1 ± 1.72 |
| Week 4: Concentration Difficulties | -2.2 ± 1.28 |
| Week 8: Concentration Difficulties | -2.3 ± 1.37 |
| Week 12: Concentration Difficulties | -2.3 ± 1.26 |
| Week 16: Concentration Difficulties | -2.3 ± 1.28 |
| Week 20: Concentration Difficulties | -2.2 ± 1.25 |
| Week 24: Concentration Difficulties | -2.3 ± 1.26 |
| Week 28: Concentration Difficulties | -2.2 ± 1.28 |
| Week 32: Concentration Difficulties | -2.2 ± 1.23 |
| Week 36: Concentration Difficulties | -2.3 ± 1.28 |
| Week 40: Concentration Difficulties | -2.3 ± 1.21 |
| Week 44: Concentration Difficulties | -2.3 ± 1.26 |
| Week 48: Concentration Difficulties | -2.4 ± 1.18 |
| Week 52: Concentration Difficulties | -2.4 ± 1.20 |
| Week 56: Concentration Difficulties | -2.4 ± 1.14 |
| Week 60: Concentration Difficulties | -2.3 ± 1.19 |
| Week 64: Concentration Difficulties | -2.4 ± 1.25 |
| Week 68: Concentration Difficulties | -2.4 ± 1.26 |
| Week 72: Concentration Difficulties | -2.4 ± 1.10 |
| Week 76: Concentration Difficulties | -2.5 ± 1.17 |
| Week 80: Concentration Difficulties | -2.4 ± 1.10 |
| Week 84: Concentration Difficulties | -2.4 ± 1.14 |
| Week 88: Concentration Difficulties | -2.6 ± 1.08 |
| Week 92: Concentration Difficulties | -2.6 ± 1.12 |
| Week 96: Concentration Difficulties | -2.5 ± 1.10 |
| Week 100: Concentration Difficulties | -2.6 ± 1.06 |
| Week 104: Concentration Difficulties | -2.6 ± 1.10 |
| Week 4: Lassitude | -2.5 ± 1.36 |
| Week 8: Lassitude | -2.4 ± 1.33 |
| Week 12: Lassitude | -2.5 ± 1.22 |
| Week 16: Lassitude | -2.5 ± 1.27 |
| Week 20: Lassitude | -2.6 ± 1.33 |
| Week 24: Lassitude | -2.6 ± 1.21 |
| Week 28: Lassitude | -2.6 ± 1.21 |
| Week 32: Lassitude | -2.5 ± 1.20 |
| Week 36: Lassitude | -2.6 ± 1.30 |
| Week 40: Lassitude | -2.5 ± 1.17 |
| Week 44: Lassitude | -2.6 ± 1.16 |
| Week 48: Lassitude | -2.6 ± 1.19 |
| Week 52: Lassitude | -2.6 ± 1.15 |
| Week 56: Lassitude | -2.6 ± 1.16 |
| Week 60: Lassitude | -2.6 ± 1.25 |
| Week 64: Lassitude | -2.6 ± 1.25 |
| Week 68: Lassitude | -2.6 ± 1.21 |
| Week 72: Lassitude | -2.7 ± 1.13 |
| Week 76: Lassitude | -2.6 ± 1.11 |
| Week 80: Lassitude | -2.8 ± 1.00 |
| Week 84: Lassitude | -2.6 ± 1.09 |
| Week 88: Lassitude | -2.8 ± 1.14 |
| Week 92: Lassitude | -2.7 ± 1.09 |
| Week 96: Lassitude | -2.8 ± 1.11 |
| Week 100: Lassitude | -2.9 ± 1.00 |
| Week 104: Lassitude | -2.9 ± 0.91 |
| Week 4: Inability to Feel | -2.7 ± 1.29 |
| Week 8: Inability to Feel | -2.6 ± 1.34 |
| Week 12: Inability to Feel | -2.7 ± 1.24 |
| Week 16: Inability to Feel | -2.8 ± 1.20 |
| Week 20: Inability to Feel | -2.6 ± 1.19 |
| Week 24: Inability to Feel | -2.8 ± 1.24 |
| Week 28: Inability to Feel | -2.7 ± 1.27 |
| Week 32: Inability to Feel | -2.8 ± 1.30 |
| Week 36: Inability to Feel | -2.8 ± 1.28 |
| Week 40: Inability to Feel | -2.8 ± 1.22 |
| Week 44: Inability to Feel | -2.8 ± 1.26 |
| Week 48: Inability to Feel | -2.7 ± 1.27 |
| Week 52: Inability to Feel | -2.7 ± 1.26 |
| Week 56: Inability to Feel | -2.8 ± 1.22 |
| Week 60: Inability to Feel | -2.9 ± 1.20 |
| Week 64: Inability to Feel | -2.9 ± 1.21 |
| Week 68: Inability to Feel | -2.8 ± 1.14 |
| Week 72: Inability to Feel | -2.8 ± 1.24 |
| Week 76: Inability to Feel | -2.8 ± 1.20 |
| Week 80: Inability to Feel | -2.9 ± 1.29 |
| Week 84: Inability to Feel | -2.9 ± 1.34 |
| Week 88: Inability to Feel | -2.9 ± 1.13 |
| Week 92: Inability to Feel | -3.0 ± 1.20 |
| Week 96: Inability to Feel | -3.0 ± 1.13 |
| Week 100: Inability to Feel | -3.0 ± 1.15 |
| Week 104: Inability to Feel | -3.0 ± 1.23 |
| Week 4: Pessimistic Thoughts | -2.0 ± 1.25 |
| Week 8: Pessimistic Thoughts | -2.0 ± 1.24 |
| Week 12: Pessimistic Thoughts | -2.1 ± 1.26 |
| Week 16: Pessimistic Thoughts | -2.1 ± 1.26 |
| Week 20: Pessimistic Thoughts | -2.0 ± 1.25 |
| Week 24: Pessimistic Thoughts | -2.1 ± 1.24 |
| Week 28: Pessimistic Thoughts | -2.1 ± 1.20 |
| Week 32: Pessimistic Thoughts | -2.1 ± 1.23 |
| Week 36: Pessimistic Thoughts | -2.0 ± 1.33 |
| Week 40: Pessimistic Thoughts | -2.1 ± 1.27 |
| Week 44: Pessimistic Thoughts | -2.1 ± 1.23 |
| Week 48: Pessimistic Thoughts | -2.1 ± 1.24 |
| Week 52: Pessimistic Thoughts | -2.0 ± 1.22 |
| Week 56: Pessimistic Thoughts | -2.0 ± 1.25 |
| Week 60: Pessimistic Thoughts | -2.1 ± 1.27 |
| Week 64: Pessimistic Thoughts | -2.1 ± 1.26 |
| Week 68: Pessimistic Thoughts | -2.1 ± 1.21 |
| Week 72: Pessimistic Thoughts | -2.1 ± 1.17 |
| Week 76: Pessimistic Thoughts | -2.1 ± 1.16 |
| Week 80: Pessimistic Thoughts | -2.1 ± 1.23 |
| Week 84: Pessimistic Thoughts | -2.1 ± 1.20 |
| Week 88: Pessimistic Thoughts | -2.1 ± 1.18 |
| Week 92: Pessimistic Thoughts | -2.1 ± 1.21 |
| Week 96: Pessimistic Thoughts | -2.2 ± 1.16 |
| Week 100: Pessimistic Thoughts | -2.2 ± 1.22 |
| Week 104: Pessimistic Thoughts | -2.2 ± 1.18 |
| Week 4: Suicidal Thoughts | -0.8 ± 1.05 |
| Week 8: Suicidal Thoughts | -0.7 ± 0.97 |
| Week 12: Suicidal Thoughts | -0.8 ± 1.05 |
| Week 16: Suicidal Thoughts | -0.8 ± 1.04 |
| Week 20: Suicidal Thoughts | -0.8 ± 1.01 |
| Week 24: Suicidal Thoughts | -0.8 ± 1.06 |
| Week 28: Suicidal Thoughts | -0.8 ± 1.02 |
| Week 32: Suicidal Thoughts | -0.8 ± 1.01 |
| Week 36: Suicidal Thoughts | -0.7 ± 1.13 |
| Week 40: Suicidal Thoughts | -0.8 ± 0.97 |
| Week 44: Suicidal Thoughts | -0.7 ± 0.91 |
| Week 48: Suicidal Thoughts | -0.8 ± 0.98 |
| Week 52: Suicidal Thoughts | -0.8 ± 0.98 |
| Week 56: Suicidal Thoughts | -0.8 ± 0.99 |
| Week 60: Suicidal Thoughts | -0.8 ± 0.97 |
| Week 64: Suicidal Thoughts | -0.8 ± 0.98 |
| Week 68: Suicidal Thoughts | -0.8 ± 0.98 |
| Week 72: Suicidal Thoughts | -0.8 ± 1.01 |
| Week 76: Suicidal Thoughts | -0.8 ± 1.01 |
| Week 80: Suicidal Thoughts | -0.8 ± 1.03 |
| Week 84: Suicidal Thoughts | -0.8 ± 0.97 |
| Week 88: Suicidal Thoughts | -0.8 ± 0.98 |
| Week 92: Suicidal Thoughts | -0.8 ± 0.97 |
| Week 96: Suicidal Thoughts | -0.8 ± 1.04 |
| Week 100: Suicidal Thoughts | -0.8 ± 1.03 |
| Week 104: Suicidal Thoughts | -0.8 ± 1.01 |
Change from Baseline of Study 54135419TRD3013 in CGI-S scale score were reported. The CGI-S provided an overall clinician-determined summary measure of the severity of the participant's illness that took into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluated the severity of psychopathology on a scale of 1 to 7: where, 1 = normal (not ill); 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participant's. Negative change in score indicated improvement. Participant's with a score of zero were considered missing.
| score on a scale | Esketamine Nasal Spray + Oral Antidepressant (AD) |
|---|---|
| Week 4 | -2.5 ± 1.00 |
| Week 8 | -2.6 ± 1.02 |
| Week 12 | -2.6 ± 0.99 |
| Week 16 | -2.6 ± 0.96 |
| Week 20 | -2.6 ± 0.96 |
| Week 24 | -2.7 ± 0.96 |
| Week 28 | -2.8 ± 0.96 |
| Week 32 | -2.7 ± 1.01 |
| Week 36 | -2.7 ± 0.99 |
| Week 40 | -2.9 ± 0.99 |
| Week 44 | -2.9 ± 0.98 |
| Week 48 | -2.9 ± 0.96 |
| Week 52 | -2.8 ± 1.00 |
| Week 56 | -2.9 ± 0.93 |
| Week 60 | -2.9 ± 0.96 |
| Week 64 | -2.9 ± 0.99 |
| Week 68 | -2.9 ± 0.93 |
| Week 72 | -2.9 ± 0.93 |
| Week 76 | -2.9 ± 0.93 |
| Week 80 | -2.9 ± 0.91 |
| Week 84 | -3.0 ± 0.86 |
| Week 88 | -3.0 ± 0.88 |
| Week 92 | -3.0 ± 0.88 |
| Week 96 | -3.1 ± 0.88 |
| Week 100 | -3.1 ± 0.87 |
| Week 104 | -3.1 ± 0.85 |
Change from Baseline of Study 54135419TRD3013 in PHQ 9-item total score were reported. The PHQ-9 was a validated 9-item, patient-reported outcome (PRO) measure to assess depressive symptoms. Each item was rated on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses were summed to a total score with a range of 0 to 27. Higher scores indicated greater severity of depressive symptoms.
| score on a scale | Esketamine Nasal Spray + Oral Antidepressant (AD) |
|---|---|
| Week 4 | -11.0 ± 5.80 |
| Week 8 | -10.9 ± 5.98 |
| Week 12 | -10.9 ± 5.73 |
| Week 16 | -11.2 ± 5.53 |
| Week 20 | -11.3 ± 5.46 |
| Week 24 | -11.3 ± 5.19 |
| Week 28 | -11.5 ± 5.25 |
| Week 32 | -11.3 ± 5.71 |
| Week 36 | -11.6 ± 6.06 |
| Week 40 | -11.5 ± 5.55 |
| Week 44 | -11.9 ± 5.67 |
| Week 48 | -11.9 ± 5.61 |
| Week 52 | -11.4 ± 5.55 |
| Week 56 | -12.0 ± 5.19 |
| Week 60 | -11.9 ± 5.24 |
| Week 64 | -11.9 ± 5.18 |
| Week 68 | -11.9 ± 5.60 |
| Week 72 | -12.1 ± 5.00 |
| Week 76 | -12.2 ± 5.12 |
| Week 80 | -12.1 ± 5.28 |
| Week 84 | -11.9 ± 5.19 |
| Week 88 | -12.2 ± 5.21 |
| Week 92 | -12.5 ± 5.11 |
| Week 96 | -12.2 ± 5.10 |
| Week 100 | -12.7 ± 4.78 |
| Week 104 | -12.7 ± 4.97 |
Change from baseline of Study 54135419TRD3013 in EQ-5D-5LQuestionnaire Score: health status index were reported. The EQ-5D-5L descriptive system comprised the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions were divided into 5 levels of perceived problems (level 1 = no problem, level 2 = slight problems, level 3 = moderate problems, level 4 = severe problems, level 5 = extreme problems). The participant selected an answer for each of the 5 dimensions considering a response that best matched participant's health "today." Responses were used to generate health status index ranged from -0.594 to 1 (where 1 represents full health and negative values represent health states considered worse than dead). Positive change in score indicated improvement.
| score on a scale | Esketamine Nasal Spray + Oral Antidepressant (AD) |
|---|---|
| Week 4 | 0.323 ± 0.2479 |
| Week 8 | 0.320 ± 0.2518 |
| Week 12 | 0.325 ± 0.2379 |
| Week 16 | 0.322 ± 0.2568 |
| Week 20 | 0.336 ± 0.2444 |
| Week 24 | 0.331 ± 0.2337 |
| Week 28 | 0.323 ± 0.2415 |
| Week 32 | 0.335 ± 0.2377 |
| Week 36 | 0.341 ± 0.2512 |
| Week 40 | 0.333 ± 0.2364 |
| Week 44 | 0.343 ± 0.2576 |
| Week 48 | 0.345 ± 0.2317 |
| Week 52 | 0.332 ± 0.2374 |
| Week 56 | 0.348 ± 0.2348 |
| Week 60 | 0.364 ± 0.2322 |
| Week 64 | 0.350 ± 0.2422 |
| Week 68 | 0.337 ± 0.2546 |
| Week 72 | 0.354 ± 0.2295 |
| Week 76 | 0.357 ± 0.2440 |
| Week 80 | 0.362 ± 0.2375 |
| Week 84 | 0.350 ± 0.2295 |
| Week 88 | 0.366 ± 0.2385 |
| Week 92 | 0.367 ± 0.2275 |
| Week 96 | 0.375 ± 0.2333 |
| Week 100 | 0.387 ± 0.2321 |
| Week 104 | 0.387 ± 0.2444 |
Change from baseline of Study 54135419TRD3013 in EQ-5D-5L: visual analogue scale were reported. EQ-VAS self-rating recorded the participant's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Positive change in score indicated improvement.
| score on a scale | Esketamine Nasal Spray + Oral Antidepressant (AD) |
|---|---|
| Week 4 | 27.35 ± 20.595 |
| Week 8 | 26.24 ± 21.939 |
| Week 12 | 26.74 ± 20.884 |
| Week 16 | 27.98 ± 20.523 |
| Week 20 | 27.85 ± 20.143 |
| Week 24 | 28.83 ± 20.438 |
| Week 28 | 28.23 ± 21.006 |
| Week 32 | 28.30 ± 21.119 |
| Week 36 | 29.99 ± 19.901 |
| Week 40 | 28.56 ± 21.210 |
| Week 44 | 29.19 ± 21.259 |
| Week 48 | 29.57 ± 21.717 |
| Week 52 | 29.60 ± 21.419 |
| Week 56 | 29.90 ± 20.828 |
| Week 60 | 30.47 ± 20.423 |
| Week 64 | 30.49 ± 20.352 |
| Week 68 | 29.82 ± 20.195 |
| Week 72 | 30.84 ± 20.252 |
| Week 76 | 31.90 ± 19.866 |
| Week 80 | 31.23 ± 20.512 |
| Week 84 | 30.40 ± 19.697 |
| Week 88 | 31.10 ± 20.469 |
| Week 92 | 31.87 ± 20.228 |
| Week 96 | 30.75 ± 19.759 |
| Week 100 | 31.66 ± 18.887 |
| Week 104 | 33.75 ± 19.356 |
Collected over From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Esketamine + Oral AD | 1/183 (0.5%) | 11/183 (6%) | 145/183 (79.2%) |
| Event | Esketamine + Oral AD |
|---|---|
| Acute coronary syndromeCardiac disorders | 1/183 |
| GoitreEndocrine disorders | 1/183 |
| Macular holeEye disorders | 1/183 |
| Alcohol poisoningInjury, poisoning and procedural complications | 1/183 |
| Multiple injuriesInjury, poisoning and procedural complications | 1/183 |
| Back painMusculoskeletal and connective tissue disorders | 1/183 |
| Brain neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/183 |
| Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/183 |
| Psychomotor hyperactivityNervous system disorders | 1/183 |
| DepressionPsychiatric disorders | 1/183 |
| Event | Esketamine + Oral AD |
|---|---|
| HeadacheNervous system disorders | 81/183 |
| DizzinessNervous system disorders | 50/183 |
| NauseaGastrointestinal disorders | 37/183 |
| NasopharyngitisInfections and infestations | 37/183 |
| VertigoEar and labyrinth disorders | 32/183 |
| COVID-19Infections and infestations | 30/183 |
| SomnolenceNervous system disorders | 24/183 |
| Back painMusculoskeletal and connective tissue disorders | 20/183 |
| DissociationPsychiatric disorders | 19/183 |
| Abdominal painGastrointestinal disorders | 15/183 |
| Age, Continuous(years) | Esketamine Nasal Spray + Oral Antidepressant (AD) |
|---|---|
| Mean | 44.6 ± 13.07 |
| Age, Customized(Participants) | Esketamine Nasal Spray + Oral Antidepressant (AD) |
|---|---|
| 18-64 years | 174 |
| >=65 years | 9 |
| Sex: Female, Male(Participants) | Esketamine Nasal Spray + Oral Antidepressant (AD) |
|---|---|
| Female | 128 |
| Male | 55 |
| Ethnicity (NIH/OMB)(Participants) | Esketamine Nasal Spray + Oral Antidepressant (AD) |
|---|---|
| Hispanic or Latino | 12 |
| Not Hispanic or Latino | 60 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Esketamine Nasal Spray + Oral Antidepressant (AD) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 6 |
| Native Hawaiian or Other Pacific Islander | 66 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Body mass index(Participants) | Esketamine Nasal Spray + Oral Antidepressant (AD) |
|---|---|
| Underweight <18.5 kg/m^2 | 5 |
| Normal 18.5 to <25 kg/m^2 | 63 |
| Overweight 25 to <30 kg/m^2 | 46 |
| Obese >=30 kg/m^2 | 41 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Apr 2021 to primary completion in Jul 2024, 38 months.
Results were first posted in Sep 2025, 1 year 1 month after primary completion.
Of 98 phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's 38 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esketamine